Ultragenyx appoints new CFO, shares fall
12/07/2023 15:52
** Shares of drugmaker Ultragenyx Pharmaceutical Inc
RARE.O down 1.4% at $43.04
** Co appoints Howard Horn as executive VP and CFO,
effective Oct. 16
** Horn joins from Vir Biotechnology Inc VIR.O , where he
served as CFO from 2017 to 2023; has also previously served as
Biogen's BIIB.O VP, strategic corporate finance
** RARE shares down ~6.6% YTD
(Reporting by Anandita Mehrotra in Bengaluru)
((Anandita.Mehrotra@thomsonreuters.com))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO